Merus N.V. (MRUS) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Utrecht, オランダ. 現CEOは Jan van de Winkel.
MRUS を有する IPO日 2016-05-19, 260 名の正社員, に上場 NASDAQ Global Market, 時価総額 $6.83B.
Merus N.V. is a clinical-stage immuno-oncology company headquartered in Utrecht, the Netherlands, focused on discovering and developing bispecific antibody therapeutics. The company's pipeline includes several candidates in various development stages, notably Zenocutuzumab (MCLA-128) in Phase 2 trials for metastatic breast cancer, along with MCLA-158, MCLA-145, MCLA-129, and ONO-4685 in Phase 1 or Phase 1/2 trials for various solid tumors and hematologic malignancies. Merus has established strategic collaborations with Betta Pharmaceuticals and Incyte Corporation to advance select candidates in its portfolio. Founded in 2003, the company leverages its bispecific antibody platform to develop novel cancer therapeutics targeting multiple pathways simultaneously.
